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SUMMARY
Electroconvulsive therapy (ECT) is utilized worldwide for various severe and treatment-resistant
psychiatric disorders. Research studies have shown that ECT is the most effective and rapid
treatment available for elderly patients with depression, bipolar disorder and psychosis. For
patients who suffer from intractable catatonia and neuroleptic malignant syndrome, ECT can be
life saving. For elderly patients who cannot tolerate or respond poorly to medications and who are
at a high risk for drug-induced toxicity or toxic drug interactions, ECT is the safest treatment
option. Organic causes are frequently associated with late-life onset of neuropsychiatric
conditions, such as parkinsonism, dementia and stroke. ECT has proven to be efficacious even
when these conditions are present. During the next decade, research studies should focus on the
use of ECT as a synergistic therapy, to enhance other biological and psychological treatments, and
prevent symptom relapse and recurrence.
Electroconvulsive therapy (ECT) is a biological treatment procedure involving a brief
application of electric stimulus to produce a generalized seizure. ECT is utilized worldwide
as one of the most effective biological treatment modalities for various severe, treatment-
refractory or treatment-resistant psychiatric disorders, in particular, major depressive
disorder (MDD) in western countries and schizophrenia in Asian countries [1]. In the USA,
approximately 100,000 patients receive ECT annually [2]. Outpatient ECT, as a continuation
treatment or an independent acute course, has become a trend over the past 20 years [2–4].
Data from the National Institute of Mental Health survey sample showed that a third of ECT
recipients were aged 65 years and older; of patients with affective disorders, 3.4% of those
under the age of 65 years received ECT, while 15.6% of those 65 years of age and older
received ECT [5].
Several factors may be relevant to a higher rate of ECT utilization in the geriatric
population. First, medication has not been more effective than placebo for treatment of late-
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life depression in several studies [6–9], particularly in depressed patients with cerebral
small-vessel disease [10–13]. Second, elderly patients have a lower tolerance to medication
owing to age-associated pharmacokinetic changes and increased sensitivity to psychotropic
medications, such as anticholinergic and orthostatic hypotensive side effects. In comparison
with pharmacotherapy, ECT may pose less risk of complications in elderly patients [14].
Third, depressed elderly patients often have a better treatment response to ECT than young
adults [15,16]. Fourth, elderly patients have higher rates of neuropsychiatric comorbidities
than younger adults. ECT can be effective in treating neuropsychiatric conditions, such as
catatonia and parkinsonism.
History of ECT
Convulsive therapy was reintroduced in 1934 by the neuropsychiatrist Meduna, who, based
on his theory of “a biological antagonism between epilepsy and schizophrenia”, chemically
induced a therapeutic generalized seizure in a catatonic schizophrenia patient [17]. In 1938,
a neurologist, Ugo Cerletti, used electricity as an alternative method of inducing a
therapeutic seizure, in the treatment of a delusional and incoherent patient, and elicited
dramatic clinical improvement. With the introduction of ECT, mortality rates in elderly
mentally ill patients were markedly reduced. A retrospective study analyzed all cases with
depression (n = 935) in a UK psychiatric hospital [18,19]. The study compared the mortality
rates between treatment as usual and ECT in patients aged 56 years and older. Between 1930
and 1939 when ECT was not available for treatment, the mortality rate was 31% (46 out of
149 patients); between 1940 and 1948, the mortality rate was 26.5% (31 out of 117 patients)
with treatment as usual, while it was 3% (one out of 35 patients) with ECT treatment. The
result is striking, indicating that ECT may have a positive impact on older mentally ill
patients. In addition, 86% of patients recovered or improved with ECT, and 60% of patients
with treatment as usual in this age group, respectively.
In the 1940s and 1950s, ECT was the mainstay of biological treatment in psychiatry. It was
often administrated to the most severely disturbed patients residing in large mental
institutions [20]. Unmodified ECT (i.e., treatment without anesthesia) was frequently given
in a higher dose for a longer period than modified ECT that is given today [20]. Harmful
events, such as fractures, dislocations and dental injury, were adverse effects associated with
unmodified ECT [21]. In the 1950s, efforts to improve the safety profile of ECT were
undertaken, including brief general anesthesia with barbiturates and succinylcholine, oxygen
supplementation and cardiopulmonary monitoring. Nonetheless, ECT was claimed to be at
least as effective and well tolerated as pharmacotherapy for unipolar and bipolar depression
in the geriatric population [22]. In the late 1970s, efforts to protect patients by standardizing
consent and the technical and clinical aspects of the conduct of ECT were undertaken in the
USA [23]; the APA Task Force was established and has recommended practice, training and
privileges standards [24].
In 1985, the National Institute of Mental Health Consensus Panel advocated research and
practice standards for ECT [25]. Following that, efforts to assure uniformly high standards
of ECT practice were promoted with the publication of guidelines by professional
organizations in the USA, England, Scandinavia and Canada, among others [26]. In the
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1980s and 1990s, evidence from both research studies and clinical practice suggested that
ECT had greater short-term efficacy than antidepressants in major depression and bipolar
depression [27–29], at least equal efficacy to lithium in acute mania [30–32], and
comparable efficacy with antipsychotics in schizophrenia/schizoaffective disorder [33–35].
Research studies also demonstrated that combined treatment with antipsychotic drug and
ECT was characterized by a faster reduction of symptom severity and lower relapse rates
compared with antipsychotic drug alone [34,36–42].
In 1990, the APA Task Force suggested ECT treatment over pharmacotherapy under certain
circumstances including: the need for rapid or definitive response; the risks of other
treatments outweighting the risks of ECT; prior treatment failure; and patient preference. In
addition, the APA Task Force also recommended that treating psychiatrists consider
unilateral ECT over bilateral (BL) ECT because unilateral electrode placement, while
providing equivalent efficacy when dosed properly, is generally associated with fewer
memory and cognitive side effects than BL electrode placement [14]. In the late 1990s, the
benefits of right unilateral (RUL) ECT were validated in control trials: RUL electrode
placement was associated with significantly fewer adverse cognitive side effects than BL
electrode placement [43]; high-dosage RUL ECT (6.0 × seizure threshold [ST]) was as
effective as high-dosage BL ECT (2.5 × ST) [43,44].
In the 2000s and 2010s, sophisticated clinical research on ECT continued to grow. In 2001,
results from a multicenter, randomized, double-blind, placebo-controlled trial showed that
nortriptyline–lithium combination therapy had a marked advantage in time to relapse,
superior to both placebo and nortriptyline alone. Over the 24-week trial, the relapse rates for
nortriptyline–lithium, placebo and nortriptyline were 39, 60 and 84%, respectively [45].
Venlafaxine combined with lithium from a recent randomized, placebo-controlled study was
shown to be equivalent to nortriptyline–lithium combination therapy in maintaining
remission post-ECT [46]. In contrast to nortriptyline, venlafaxine is well tolerated and has a
better safety profile for elderly patients. Continuation ECT (C-ECT), shown to be at least
equivalent to continuation pharmacotherapy, is an excellent alternative for elderly patients
who cannot tolerate medications or who relapse on adequate post-ECT pharmacotherapy
after a successful course of ECT.
Evidence base for ECT effectiveness, efficacy & tolerability in older adults
Major depressive disorder
The three leading causes of disease burden in 2030 are projected to be HIV/AIDS, unipolar
depressive disorders and ischemic heart disease. Unipolar depression was ranked the fourth
cause of disease burden in 2002; and it is projected to be the second worldwide and the first
in high-income countries (e.g., USA) in 2030 [47]. Depression is highly comorbid with the
other two leading causes, HIV/AIDS and ischemic heart disease [48,49]. The prevalence of
major depression was 5.5% in individuals over 65 years of age [50]. The highest prevalence
of major depression was in nursing homes and other residential settings [51]. Untreated and
undertreated elderly with major depression have higher rates of mortality and morbidity
[52,53]. Although it is a treatable illness, major depression can be chronic and recurrent.
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The efficacy of ECT in major depression is well established. Data from comparative trials
showed that the antidepressant effects of ECT are greater than any pharmacologic agent,
including monoamine oxidase inhibitors [54], tricyclics [29,55,56], and serotonin reuptake
inhibitors [28]. A large, multisite collaborative study showed that, among 217 patients, 86%
completed an acute treatment course with three-times a week BL ECT, 79% showed
sustained improvement and 75% remitted [57]. This study suggests that ECT has a rapid
effect and high remission rates compared with 25–35% remission rates with
pharmacotherapy [58]. For pharmacotherapy treatment-resistant major depression, 50% or
more can respond to ECT [59,60].
A large body of literature indicates that ECT is an effective and safe treatment option for
elderly patients with major depression, even in very old-old age (>85 years). Efficacy of
ECT is markedly greater in older patients as compared with younger patients [16,61–63].
Yet, an observational study found that the time course of response to ECT can be variable,
possibly longer for elderly patients. Hence, the study suggests that ECT should not be
abandoned when rapid response is not seen [64]. From a long-term care prospective, results
from a survival analysis of a large follow-up study showed that older adults with major
depression, who received ECT, lived longer and had a greater clinical improvement
compared with patients who received treatment with pharmacotherapy only [65].
Subtypes of major depression
Melancholic depression is a severe form of major depression with the loss of capacity to
derive pleasure from positive stimuli and a high rate of hospitalization. It is commonly seen
in late-onset major depression (≥60 years) [66]. Owing to its distinct clinical features,
researchers had investigated whether melancholic depression responds to ECT differently
from other affective disorders. Early case reports and series suggested that melancholic
features could predict a positive outcome with ECT, but more recent studies found that
melancholic features were less reliable predictors. Data from a the Consortium for Research
on Electroconvulsive Therapy (CORE) study involving 311 patients with MDD found that
ECT remission rates were 62.1% with melancholic MDD and 78.7% non-melancholic
MDD. During a 6-month follow-up, patients with melancholic features were less likely to
relapse with C-ECT than with continuation pharmacotherapy (nortriptyline plus lithium)
[67]. For patients who have a partial response to ECT, melancholic features have little
predictive value [68]. For ECT-naive patients, although increasing stimulus intensity might
yield a more rapid onset of response, ECT does not affect the degree of melancholic
symptom improvement or number of ECT required to achieve a therapeutic response in a
large randomized trial [69].
Delusions have a higher prevalence in late-onset major depression (>60 years of age) [70]. A
retrospective review concluded that depressed patient with psychotic delusion can be five
times more likely to commit suicide than a nondelusional one [71]. Overall, delusional
depression has a poorer prognosis than nonpsychotic depression [72], and is less responsive
to antidepressants [73]. ECT was significantly more effective than sham ECT in delusional
depression as documented in three double-blind, placebo-controlled trials (Leicester,
Northwick Park and Nottingham). However, studies found the differences of ECT response
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rates between delusional and nondelusional depression were not large [74], but remission
rates were greater and symptoms improved earlier with ECT in delusional depression [75].
Currently, patients referred for ECT are those who need rapid treatment response in the
setting of failed multiple antidepressant trials, as well as combined treatment with
antidepressants and antipsychotic drugs. For elderly patients with severe depression and
psychotic features, ECT may be the most effective and rapid treatment available [14,76].
Bipolar disorder
A community-based epidemiological study reported the prevalence of bipolar disorder in
adults over 65 years was 0.08% [77]. However, a survey of nursing home elderly residents
reported the prevalence of bipolar disorder was 10% [78], and the Veterans Affairs
Hospitals in federal fiscal year 2001 showed that 24.9% of bipolar patients were over 60
years of age [79]. Late-life onset of bipolar disorder is highly associated with
neuropsychiatric conditions [80]. Hence, older adults who present with new-onset mania
should have a complete medical evaluation and a neuropsychiatric work-up before ECT.
Pharmacotherapy is the first-line treatment for bipolar disorder and lithium is the oldest
effective mood stabilizer for bipolar disorder. However, elderly patients have poorer
tolerance of lithium compared with younger patients. First, age-related pharmacokinetic
changes, including absorption, distribution, plasma protein-binding, hepatic metabolism and
renal clearance, predispose older patients to a higher risk of lithium toxicity [81]. Second,
lithium neurotoxicity (e.g., sedation, confusion, delirium and memory impairment) can
occur even within therapeutic range in older individuals owing to age-dependent changes in
tissue sensitivity to the action of the drug (pharmacodynamics) [82]. Third, serum lithium
levels can significantly increase due to drug–drug interactions between lithium and
medications frequently prescribed for elderly, such as thiazide diuretics and ACE inhibitors
for hypertension, and NSAIDs for arthritis [83]. However, other medication options for
bipolar disorder also have unfavorable side effects and significant drug–drug interactions,
for example, carbamazepine is a potent CYP450 inducer and valproic acid is a potent
CYP450 inhibitor.
ECT is highly effective for bipolar depression, with no reported difference in degree of
improvement in bipolar depression compared with unipolar depression [84]. Daly and
colleagues [87]contrasted a sample (n = 228) from three double-blind trials [43,85,86]
conducted in an academic medical center, and found that ECT for bipolar depression was as
effective as for unipolar depression regardless of anatomical positioning of the electrode
placement. Moreover, there were significantly more rapid clinical improvement and shorter
treatment course in bipolar depression than in unipolar depression [87]. A recent study of
hospitalized patients treated with ECT reported that the number of treatments needed to
achieve remission in patients with bipolar depression (mean ± standard deviation: 7.5 ± 1.6)
was lower than in patients with unipolar depression (mean ± standard deviation: 10.2 ± 1.9)
[88]. Several studies suggested that fewer ECT treatments were required to achieve
comparable benefits in bipolar disorder than unipolar depression [84,87–89]. Therefore,
ECT can be an excellent alternative treatment option for elderly patients with bipolar
disorder who cannot tolerate pharmacotherapy.
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ECT has been used to treat mania since the 1940s. The paucity of rigorous clinical trials to
support the antimanic effects of ECT is a major factor limiting the use of ECT for mania. In
addition, early case reports and series might have discouraged the use of ECT for mania
because extended courses of ECT and/or frequent treatment (i.e., daily ECT) were
recommended to achieve symptom improvement or remission [90]. More recent studies
have shown that remission rates for mania are greater than for bipolar depression after an
acute course of ECT [91]. A second factor limiting the use of ECT for the treatment of
mania is the substantial efficacy of mood stabilizers for mania, including antiepileptic drugs,
lithium and antipsychotics/atypical antipsychotics. One early-controlled study, conducted
before pharmacotherapy was standard for mania, assessed the efficacy of ECT compared
with conservative treatment (control group). Both the ECT group and the control group
consisted of 17 women and 11 men with a mean age of 33 years. Results from the study
showed that ECT had a favorable treatment outcome compared with conservative treatment:
the average length of hospital stay was 6.5 ± 2.13 days in the ECT group and 15.3 ± 11.3
days in the control group, and the overall symptom improvement was 96% in the ECT group
and 44% in the control group [92]. The advantage of this study is that patients in both the
ECT group and the control group were drug naive, which made the comparison more
compelling. Nevertheless, this study was a retrospective study and the design was not
randomized or double blind. Later studies found that the effectiveness of ECT was superior
to lithium during the acute treatment phase, but the superiority did not extend behind 8
weeks [30,93]. However, patients who received ECT had longer remissions [93] and a lower
risk of rehospitalization [94]. By contrast, Medda’s study found that patients with bipolar I
tended to exhibit residual manic and psychotic symptomatology after an acute ECT course
with BL ECT [95].
It is controversial whether the difference in anatomical positioning of electrode placement
has a significant impact on the efficacy of ECT in bipolar mania. Some have suggested that
unilateral ECT had no effect on mania while strongly supporting the effects of BL ECT
[96,97]. For instance, one case series reported that six manic patients did not improve with
unilateral ECT but showed clinical improvement after switching to BL ECT [98]. However,
such results could be confounded by a requirement for a longer treatment course in the
reported cases. By contrast, other studies found unilateral ECT and BL ECT to be equally
effective for mania [91,99]. One study compared the efficacy of ECT in treatment-resistant
mania using unilateral and BL electrode placement. Results from the study showed that
among 13 acute manic patients randomized to unilateral ECT, seven were responders and
six were nonresponders; among 11 patients randomized to BL ECT, six were responders and
five were nonresponders. There was no difference in treatment response associated with the
anatomical positioning of the electrode placement in this study [99]. The strengths of this
study is that the comparison was based on a medication-resistant sample and the study had a
randomized design. Various factors might have attributed to the contradictory results from
different reports in addition to study design, such as stimulus intensities, distance between
the electrodes and sample selection [99].
A recent retrospective chart review of 65 bipolar patients who received ECT found robust
response rates in all bipolar patients, including bipolar depressed, mania and mixed state.
The number of ECT treatment was greater in mixed states compared with bipolar
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depression, suggesting mixed states might be more difficult to treat [100]. In a naturalistic
study, 43 patients with rapid cycling were observed for 2–36 years following an index ECT
course. The study found an acute course of ECT did not extinguish rapid cycling: 33 out of
43 patients continued to suffer from rapid cycling after only a brief improvement following
an acute course of ECT. However, in the same study, two out of three patients who received
continuation or maintenance ECT (M-ECT) were recovered at 2 years [101]. Some case
reports stated that rapid cycling or mixed states can develop when off lithium during an ECT
course [102]. For this reason, continuation of lithium during a course of ECT has been
recommended, if twice-weekly treatment frequency is used. Studies have shown
continuation of lithium during a course of ECT is safe and not associated with higher
frequency of adverse effects [103,104], when lithium is held 24 to 36 h before each ECT
treatment session. Delirious mania with catatonic features is a severe form of mania,
particularly in elderly patients with medical conditions. Fortunately, delirious mania and
catatonia are highly responsive to ECT, which can be life saving (see the ‘Catatonia’
section).
Efficacy and effectiveness of ECT for medication-resistant mania became a focus in later
research, after lithium and other neuroleptic drugs were used as first-line treatment for
mania. Results from a critical literature review before 1994 found that 80% of medication-
resistant manic patients achieved remission or, at least, had a marked clinical improvement
following an acute course of ECT [105].
Schizophrenia & nonaffective psychotic spectrum disorders
Schizophrenia is a serious debilitating mental illness that affects 1% of the population
world-wide. In total, 65% of schizophrenia patients are also reported to experience at least
one depressive episode at 20-year follow-up, with completed suicide rates of 10% at 10
years and 12% at 20 years [106]. Treatment options for schizophrenia were revolutionized
by the introduction of pharmacotherapy in the 1950s. Lacking evidence of superiority of
ECT over medication beyond an acute treatment phase [34], ECT is no longer used as a
first-line treatment for chronic schizophrenia.
In 1985, a NIH Consensus Conference Panel recommended ECT for schizophrenia with
acute onset and a shorter duration [20]. In 1990, the APA Task Force on ECT sanctioned the
use of ECT for schizophrenia with prominent affective features or catatonia during
exacerbations [14]. In the meantime, research also found that ECT was more effective in
schizophrenia patients with excitement, delusions or delirium [33]. Tharyan and colleagues
analyzed 26 randomized controlled trials (RCTs) trials from 1982 to 2004 and found that the
ECT groups (n = 392; ten RCTs) had greater improvement, fewer relapses (n = 47; two
RCTs) and a greater likelihood of being discharged from a hospital (n = 98; one RCT).
However, the superiority of ECT over medication did not last after an acute course of
treatment [36]. Another literature review suggested several factors might be associated with
positive predictive value of ECT, such as delusions, hallucinations, affective or catatonic
symptoms, absence of negative symptoms and a short duration of the current episode [107].
In recent years, clinical studies have focused on the treatment of medication-resistant
schizophrenia. Results from a meta-analysis, involving 11 uncontrolled trials and four
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controlled trials, suggest the combination treatment of ECT and antipsychotic drugs is more
effective than antipsychotic drug alone during an acute treatment phase [108]. This regimen
may be an option for schizophrenia patients who need rapid symptom control or who are
medication resistant [36]. Results from a naturalistic retrospective study suggest that
augmentation of ECT with clozapine is safe [109] and may be effective in treatment of
clozapine-resistant schizoaffective disorder [110]. Some authors suggested a repeat course
of ECT or a longer initial course of ECT could be effective in clozapine-resistant
schizophrenia patients [111]. National and international ECT practice guidelines currently
recommend ECT as an augmentation strategy in treatment-refractory schizophrenia during
acute exacerbation or continuation therapy [107].
Catatonia
Catatonia is a complex and heterogeneous syndrome, which consists of motor abnormalities
that occur in association with changes in thought, mood and vigilance. The underlying
etiology of catatonia is complex, including psychiatric illness, medical conditions and
neuropsychiatric illnesses. Malignant catatonia is the most severe form of catatonia, and can
be complicated by life-threatening medical conditions (e.g., dehydration, infection, stroke
and deep venous thrombosis), autonomic instability and systemic organ failure [112]. Older
adults are particularly susceptible to developing malignant catatonia [113]. It can be lethal if
unrecognized or misdiagnosed [114,115]. ECT can be life saving for older adults who
exhibited symptoms of malignant catatonia or acute catatonia [113,116].
Catatonic symptoms are the most responsive to ECT, even more so than positive psychotic
symptoms such as paranoid delusions or affective symptoms [117]. Elderly schizophrenia
patients with intractable catatonia often experience medication resistance, medication
intolerance or severe medical conditions, but can be treated effectively with acute ECT
[118]. For schizophrenia patients with catatonia who relapsed after a positive response to
acute ECT, a combination of C-ECT and neuroleptics has been shown to maintain
improvements in symptoms [42,119]. Overall, elderly schizophrenia patients with
intractable catatonia tolerated ECT well. Elderly patients with major depression have the
highest prevalence of catatonia [120]. A naturalistic retrospective study found post-ECT
treatment with lithium or antidepressants, such as tricyclics, bupropion and venlafaxine, but
not selective serotonin reuptake inhibitors, had an excellent long-term outcome in elderly
depressed patients with catatonia in a 4-year follow-up study [121]. Taylor and Abrams
[122] reviewed 123 manic patients and found that 28% of them exhibited clinical signs of
catatonia. Catatonic symptoms are associated with a more severe course in mania. Delirious
manic patients often presented with dehydration, fever, elevated blood pressure and rapid
heart rates [123]. ECT has been shown to be an effective and safe treatment for delirious
mania with catatonic features [123].
Catatonic patients may initially present with worsening psychotic or behavioral symptoms,
such as disorganization, confusion, extreme negativism, agitation and aggression. These
patients can be at high risk of developing neuroleptic malignant syndrome (NMS) when
receiving high potency neuroleptic drugs [124–127]. NMS is an uncommon adverse effect
of antipsychotic drugs, but can lead to a life-threatening condition characterized by severe
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rigidity, tremor, fever, altered mental status, autonomic dysfunction, and elevated serum
creatinine phosphokinase and white blood cell count. ECT is highly effective for NMS with
significant clinical improvement after a few treatments [128]. Malignant catatonia and NMS
both can be lethal but are reversible conditions, and have a good prognosis when adequate
treatment is received promptly. The combination of ECT and lorazepam is highly effective
for malignant catatonia secondary to NMS [116,129,130]. Some authors suggested that
catatonia is a risk factor for NMS and proposed a hypothesis that NMS was a variant of
malignant catatonia [126,127,131,132]. However, the link between NMS and malignant
catatonia has not yet been confirmed.
Catatonic symptoms in elderly patients can be masked by concurrent medical and
neurological conditions [113,114,133,134], such as infectious disease (e.g., pneumonia and
advanced syphilis), cardiovascular disease, cerebrovascular disease, renal failure, dementia
with Lewy bodies or advanced Parkinson’s disease, and dementia. Benzodiazepines are used
as first-line treatment for mild-to-moderate catatonia [135]. Some authors have also
suggested alternative medications for elderly catatonic patients, such as midazolam [136],
memantine [137,138], topiramate [139] and amantadine [140]. ECT can be very effective for
medication-resistant catatonia [134,135,141]. A combination of benzodiazepines and ECT
has shown to be highly effective for NMS, malignant catatonia, and residual or refractory
catatonia [127,142].
Parkinson’s disease & parkinsonism
In addition to motor abnormality, patients with Parkinson’s disease may also suffer from
cognitive impairment, depression and anxiety. Pharmacotherapy is available for
symptomatic treatment, but can be accompanied by side effects with both L-dopa and
dopamine agonists, such as frank hallucinations (usually visual hallucinations), paranoia or
delusions, mania and anxiety [143]. Atypical antipsychotics with fewer extra-pyramidal side
effects, such as quetiapine and clozapine (off label), are often used to manage hallucinations
and psychosis associated with dopaminergic treatment. ECT can be an effective treatment
for patients who develop antiparkinsonian drug-induced psychosis and antipsychotic drug-
refractory psychosis, or who have antipsychotic-induced intractable movement disorders
despite discontinuing offending agents [144]. There is a higher prevalence of parkinsonism
in elderly patients who were exposed to antipsychotic drugs [145–147]. Elderly patients with
parkinsonism may lose self-care capacity, which may lead to drug treatment noncompliance.
Case reports and series demonstrated that ECT was an effective treatment for antipsychotic-
induced severe or persistent parkinsonism [148–151], suggesting that ECT may be an
alternative treatment option if resolution of movement complications is required.
It is challenging to treat movement symptoms of idiopathic Parkinson’s disease. As
Parkinson’s disease progresses, patients often suffer from ‘on–off ’ phenomena, in which a
higher or more frequent dose of antiparkinsonian drugs may be required during the ‘on’
period in order to maintain motor function during the ‘off’ period. However, high-dose
antiparkinsonian drugs can cause significant adverse effects including psychiatric
symptoms. In a placebo-controlled, double-blind study, 11 patients with severe Parkinson’s
disease and ‘on–off ’ phenomena were treated with ECT or sham ECT. The results of the
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study showed that patients treated with real ECT had a significantly prolonged duration of
‘on’ period compared with those treated with sham ECT [152]. Relevant mechanisms of
action may involve increasing the responsiveness of postsynaptic dopamine receptors
[152,153] and norepinephrine receptors [154], or dopamine transporter uptake [155]. In a
pilot study, the use of ECT can prolong antiparkinsonian drug effects in Parkinson’s disease
with medication resistance [156]. M-ECT can be used as an adjunct treatment in some
patients who are refractory to antiparkinsonian drugs [157].
The most common adverse effects of ECT in patients with Parkinson’s disease are transient
delirium, confusion, amnesia and cognitive impairment [156]. Dosage of L-dopa or
dopamine agonists may need to be reduced to avoid post-ECT delirium and dyskinesis
[158]. Overall, ECT is safe, effective, and well tolerated in elderly patients with Parkinson’s
disease and parkinsonism.
Dementia
Dementia is one of the major causes of disability in the geriatric population. Alzheimer’s
disease is the leading cause of dementia (60–70%), followed by vascular dementia and
dementia with Lewy bodies [159,160]. A total of 30–40% of demented patients have
psychotic symptoms [161–163], 40–60% have depressive symptoms [164,165], and 17–30%
have been diagnosed with major depression [165,166]. One out of six demented patients
with major depression received ECT in a US national survey sample [167]. When
underlying affective or psychotic symptoms are successfully treated with ECT, cognitive
deficits may improve in some but not all demented patients with concurrent major
depression [168,169]. A chart review from case reports and series in the 1980s found 30%
(six out of 19 cases) of primary degenerative dementia with major depression had cognitive/
memory improvement after receiving ECT [168]. Other studies found that vascular dementia
and clinically nondemented patients with MRI cerebral signal hyperintensity had cognitive
decline or transient worsening after ECT, even though depression was successfully treated
with ECT [168,170].
Agitation, aggression and other behavioral disturbances are observed in up to 70% of
patients with advanced dementia, and 25–35% of demented patients exhibit physical
aggression or serious self-injurious behavior [171]. Atypical antipsychotic drugs are often
used to manage severe behavioral disturbances and psychosis in demented patients [172–
174]. However, positive symptom improvement is not sizeable. In a 42-site, double-blind,
placebo-controlled trial, 421 outpatients with Alzheimer’s disease and psychosis, aggression
or agitation were randomly assigned to receive olanzapine (mean dose: 5.5 mg per day),
quetiapine (mean dose: 56.5 mg per day), risperidone (mean dose: 1.0 mg per day) or
placebo. Patients were followed for up to 36 weeks. Results from this study did not find that
atypical antipsychotics were superior to placebo [175]. ECT, used as an alternative treatment
when other treatment options were exhausted, has been shown to be effective in many
uncontrolled case series, although the focal point of these studies was the benefit of ECT for
short-term behavioral control [176,177]. Data supporting effectiveness of ECT for agitation/
aggression in demented elderly patients are limited. There has yet to be a comparison of the
efficacy of ECT and antipsychotic drugs for treatment of demented patients with severe
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behavioral disturbances. ECT is currently considered to be a last resource for the treatment
of agitation/aggression in patients with dementia.
Postictal prolonged confusion and worsened cognitive or memory function may occur in
some demented patients who received BL ECT. However, these adverse effects were
reported to be transient and reversible in most cases, ranging from a few days to a few
months [168,177,178]. Older age, pre-existing cognitive impairment, coadministration ECT
with other drugs and medical comorbidities may also be contributing factors. In general,
ECT is safe and effective in treating patients with Alzheimer’s dementia and severe
behavioral disturbances, major depression, mania and psychosis [177].
Stroke
Prevalence of poststroke depression was 34% compared with 13% in older adults in the
general population [179]. Most episodes of poststroke depression occur in the first 2 years
after a cerebrovascular incident. The location of a lesion, particularly its proximity to the left
frontal pole, has a profound impact on the frequency and severity of poststroke depression
[180]. Poststroke mania is uncommon but can be clinically significant when lesions are
within the right hemisphere [181]. A literature review of five randomized, placebo-
controlled antidepressant trials for poststroke depression concluded that antidepressants
could reduce the frequency and severity of crying or laughing episodes, but the efficacy of
treating mood symptoms was very limited [182]. A retrospective study reviewed charts of
20 elderly patients who received ECT for poststroke depression and reported that 95% of
patients improved with ECT and 15% of patients had transient interictal confusion or
amnesia. No patient experienced acute exacerbation of pre-existing neurologic deficits in
this study [183]. These findings indicate that ECT is generally well tolerated and effective
for post-stroke depressed elderly patients, suggesting ECT should not be withheld from such
patients.
Pre-ECT evaluation
A multidisciplinary approach to ECT is essential. Minimally, a treating psychiatrist, an ECT
psychiatrist (who may be the same) and an anesthesiologist should evaluate the patient’s
current and past history of psychiatric illness, substance dependence, neuropsychiatric and
medical conditions, and prior anesthesia. A baseline cognitive assessment, such as mini
mental state examination is recommended. Patients with abnormal findings on neurological
exam or neuropsychiatric testing should be referred for neuroimaging to rule out CNS
pathology prior to ECT. For elderly patients who have sudden onset of psychiatric
symptoms, personality change, neuropsychiatric conditions or significant medication
resistance, brain imaging (e.g., MRI) should also be obtained. Baseline (prior to ECT)
neurocognitive assessments (e.g., subjective and objective assessments of memory function)
[184,185] and global impact of ECT on mood or memory [186] can be very informative
when evaluating post-ECT cognitive functioning, particularly in elderly patients who have
pre-existing cognitive and memory impairment.
From a medical standpoint, any significant medical comorbidity should be evaluated in
consultation. A medical specialist may need to be included in the multidisciplinary team.
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Current dental conditions (e.g., dentures, loose teeth and oral malformation) should be
assessed in order to provide for a secure airway during ECT under general anesthesia. Basic
laboratory tests prior to ECT should include complete blood count, basic metabolic panel
and ECG. It is important to review current medications because they may have significant
negative impact on the efficacy of ECT, patient safety and post-ECT recovery.
Written informed consent for ECT is the standard of care. ECT consent is locally regulated
[187], particularly at the state level. ECT is not comparable with other life-saving medical
procedures or treatment where consent can be obtained after the procedure or treatment in
emergencies. If a patient does not have capacity for informed consent or there is no legal
surrogate available, a court order may be an alternative. Consent can include both anesthesia
procedures and the electrical stimulation. One informed consent is recommended for the
acute phase of ECT while a separate consent is recommended for M-ECT. Informed consent
should include risks and benefits comparable to a standard medical procedure consent form.
The possibility of relapse and nonresponse should be addressed in the consent form,
according to the nature of psychiatric pathology. An approximate number of treatments
should be discussed with the patient or his surrogate, and this information can be included in
the consent form. It is important to inform the patient or his surrogate that ECT consent can
be withdrawn anytime.
Maximizing ECT efficacy & minimizing ECT side effects
Stimulus waveform
Sine wave stimulus has been replaced by brief pulse stimulus since 2001, when professional
organizations recommended discontinuing use of sine wave stimulation. Ultrabrief pulse
was reintroduced in the late 1990s and in RCTs [188–190]. Ultrabrief pulse has been shown
to be a more efficient method of delivering electrical dose regardless of anatomical
positioning of electrode placement [188]. The use of ultrabrief pulse stimulation allows a
wide range of effective stimulus dose on currently marketed devices (Table 1). There is
growing data on the efficacy of ultrabrief pulse ECT, which appears to be effective while
reducing adverse cognitive effects. It is currently not advised to practice ultra-brief BL ECT
outside of research settings [191].
Anesthesia
Individual anesthetic agents and muscle relaxants have different benefit and side-effect
profiles (Table 2). Methohexital has been a standard anesthetic agent for ECT. In contrast
with methohexital and pentothal, propofol is less often used because propofol significantly
shortens seizure duration, an observation that has prompted concern about effects on clinical
outcomes. Subsequent studies have not shown reduced benefit with propofol.
Succinylcholine is the most commonly used relaxant for ECT. However, it should be
avoided if a patient has a history of malignant hyperthermia. Succinylcholine should not be
used in a patient with atypical plasma cholinesterase. When needed, mivacurium is an
alternative to succinylcholine.
Kerner and Prudic Page 12























Adverse cognitive effects associated with ECT can be persistent or even profound in some
individuals. Anatomic positioning of the electrode placement is strongly associated with
such cognitive deficits (Table 3). The severity and duration of retrograde memory
impairment for autobiographical events are greater in patients receiving BL electrode
placement than RUL electrode placement. Current data supporting the efficacy of bifrontal
(BF) ECT are limited. A meta-analysis of eight RCTs, comparing efficacy and side effects
of BF ECT to bitemporal or RUL ECT in depression, concluded that BF ECT is not more
effective than BL or RUL ECT, but may have potential advantages over BL ECT for
specific memory domains [192].
Electrical stimulus & seizure threshold
Electrical signals have three variables: current, voltage and impedance (resistance). The
relationship among these variables is: current = voltage/resistance. Manipulation of both
current and voltage can yield different stimulus intensity. The majority of available devices
are constant-current devices, and all devices marketed in the USA are constant-current. The
three predictive variables associated with seizure threshold are electrode placement, gender
and age [193–195]. Seizure threshold is higher in BL electrode placement compared with
unilateral electrode placement, in male patients and elderly patients. The stimulus dose is
controlled by frequency of pulses, pulse width, duration of pulse train, and pulse amplitude.
Each exerts unique neurobiological effects. Determining chronaxie is the standard method
for determining optimal pulse width in neurostimualtion. Studies have shown the chronaxie
for mammalian neuronal depolarization is 0.1–0.2 ms. Standard ECT stimulus has had a
pulse width between 0.5 and 2 ms. Reduction of pulse width to physiologic range results in
markedly reduced adverse effects while maintaining efficacy, except possibly BL electrode
placement [190].
Traditionally, there was a widely held belief that the efficacy of ECT depended exclusively
on whether or not a seizure was induced successfully; and stimulus dosing was responsible
for cognitive side effects [196,197]. However, data from the controlled trials do not support
this belief. The combinations of anatomical positioning of electrode placement and stimulus
dose produce clinical efficacy, ranging from 20 to 80% in remission rates [43,57,85],
depending on how the treatment is performed. RUL electrode placement is particularly
affected by stimulus dose, and a dose-response relationship exists up to a stimulus intensity
of 8–12 times the seizure threshold. RUL ECT is less effective when an electrical dose is
given close to seizure threshold [85]. A markedly suprathreshold dose improves the efficacy
of RUL ECT to a level comparable to BL ECT, shortens the time to achieve clinical
responses in both BL and unilateral ECT, but yields more short-term cognitive side effects
[85,198].
Titration & dosing
Empirical titration gives the most accurate estimation of seizure threshold currently
available. Clinicians can calculate stimulus intensity based on the seizure threshold. The
therapeutic stimulus intensity for unilateral ECT is 2.5–8 times of seizure threshold, which
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produces the highest efficacy of ECT [44]. High-dosage RUL ECT (6.0 × ST) is as effective
as high-dosage BL ECT (2.5 × ST) [43,44].
ECT adverse effects & management
ECT carries risks, similar to all other medical procedures and treatments. The most common
somatic side effects of ECT are headaches (48%), muscle pain (15%), dry mouth (23%),
nausea (23%) and tiredness (73%) [86]. The most common cognitive side effects are
anterograde memory impairment (41%) and confusion (37%) [86]. The most concerning
adverse effects related to ECT in elderly patients are cardiac or pulmonary complications,
post-ECT delirium/confusion and persistent memory impairment. However, ECT has lower
risk of complications than some forms of pharmacotherapy in elderly patients [14].
Mortality & medical complications
Mortality rates associated with ECT have declined: 2–10 per 100,000 ECT treatments in the
1990s [199] and less than one per 100,000 ECT treatments in more recent studies [200,201].
Although there are no ‘absolute’ medical contraindication to ECT, the cardiovascular system
and the CNS are two organ systems of critical importance when considering the medical
risks of ECT. Specific conditions may increase the mortality risk associated with ECT,
including a recent myocardial infarction, poorly compensated congestive heart failure,
severe cardiac valvular disease, cerebral aneurysm, cerebrovascular malformation, brain
lesions with increased intracranial pressure, a recent stroke/hemorrhage, severe chronic
obstructive pulmonary disease, asthma, or pneumonia, and American Society of
Anesthesiologists level 4 or 5 [187].
Older age per se is not a risk factor for mortality associated with ECT, although older adults
may be at a greater risk because of a higher prevalence of medical comorbidity. A
retrospective review of 2279 charts of patients who underwent 17,394 ECT at a single
institution in a 13-year period reported that 21 (0.92%) patients experienced complications
at some time during the course of ECT, including five respiratory events (slow awakening,
bronchospasm, apnea and respiratory arrest) and nine cardiac events. All of the patients who
experienced cardiac event(s) had a history of cardiovascular disease prior to ECT. The
majority of the cardiac events were arrhythmias (ventricular tachycardia, ventricular
fibrillation and bradycardia with second degree heart block) and the rest had ischemic
changes on ECG. One patient had asystole during ECT. There were no deaths, permanent
injuries or disability related to ECT. The complication rate was 0.08% per ECT treatment
[201]. A 3-year follow-up study reported 519 depressed patients who received ECT had a
lower mortality than the antidepressant treatment group [21]. Therefore, early intervention
and effective treatment of depression can be life saving. For elderly patients with severe
depression and comorbid cardiac conditions who can not tolerate or are refractory to
antidepressant treatment, ECT can be a fast and effective treatment for depression [63].
Cardiac complications
Rasmussen et al. described the normal cardiac physiology of ECT [202]. Initially, the
parasympathetic nerve system is activated by electrical stimulus via the vagus nerve, and
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there is a sharp transient decreased HR and BP (10–15 s). Sympathetic nervous system
output becomes predominant as soon as the seizure begins and a catecholamine surge
occurs. The HR increases 20% or more, and the BP increases 30% or more during a seizure.
Prudic and colleagues studied 34 patients who received ECT for major depression and found
that those with high baseline HRs had smaller increases in peak postictal HR and BP;
baseline HR predicts peak ECT postictal change of HR and BP, but not baseline BP [203].
Generally, vital signs return to baseline within minutes of the end of the ictal period. Healthy
individuals can tolerate these transient autonomic changes without adverse outcome.
However, when electrical stimulus does not have sufficient intensity to cause generalized
seizure, some patients may develop bradycardia or even asystole due to persistent
parasympathetic effect. A low dose of atropine (0.2–0.6 mg) can be sufficient to prevent
severe bradycardia and asystole, particularly during seizure threshold titration sessions. A
higher dose of atropine should not be administered to elderly patients, because it might
contribute to postictal delirium or confusion, and urinary retention [202]. Glycopyrrolate
(0.1–0.03 mg intravenously) can also effectively prevent asystole during titration. Although
rare, supraventricular tachycardia is more commonly found with use of anticholinergic
agents [204].
Although both the prevalence and severity of hypertension increase markedly with
advancing age [205], the transient autonomic changes during ECT are well tolerated by
elderly patients with controlled hypertension [206]. For patients who have uncontrolled
hypertension, the condition should be treated before receiving ECT treatment [207]. Short-
acting β-blockers, such as esmolol and labetalol, have been used in attenuating HR and BP
responses to sharply increased sympathetic output during ECT [208]. However, pretreatment
with low-dose esmolol had led to decrease seizure duration that reduced the efficacy of ECT
in a double-blind, placebo-controlled study [209]. A retrospective study found no evidence
that ECT caused sustainably increased BP, either in hypertensive or nonhypertensive
patients during the course of ECT [210].
When a patient has pre-existing cardiovascular conditions, such as ischemic heart disease,
congestive heart failure or valvular disease, cardiac compromise may occur during ECT.
Zielinski and colleagues compared the rate of complications of ECT between 40 elderly
depressed patients with cardiac disease and 40 matched depressed patients without cardiac
disease [211]. The study found that the patients with cardiac disease had a significantly
higher rate of cardiac complications (minor and major) during ECT than the comparison
group without cardiac disease. All ischemic events occurred in patients with known
ischemic heart disease or myocardial infraction. There was no death in this study. Pre-
existing cardiac abnormality strongly predicted the type of cardiac complication that may
occur with ECT. The study also found no significant difference in age, number of ECT per
patient, anesthetic used or electrode placement, comparing the subgroups with major, minor
or no complications.
For patients with less than 25% ejection fraction, complication rates increase dramatically.
Treatment for congestive heart failure before ECT should be optimized. Stern and
colleagues described three patients who had congestive heart failure with low ejection
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fraction (26, 25 and 20%) [212]. These patients received optimal treatment of congestive
heart failure before ECT. All three cases were successfully treated with ECT without major
complications during and post-ECT. The authors proposed a protocol for patients with low
cardiac output: administration of regular cardiac medications 60–90 min before ECT; a 5-
mg nitroglycerine adhesive plaster 30 min before ECT; sublingual nifedipine 20–30 min
before ECT; intravenous labetalol (5–15 mg) 5–10 min before ECT, avoidance of
anticholinergic medications. Prophylactic intravenous β-blocker has been suggested for
patients who had marked hypertension during previous ECT sessions (e.g., systolic BP over
180 mmHg) or a HR greater than 100 beats per minute, in a retrospective chart review study
[213]. Patients with large aneurysms or severe valvular heart disease may need surgical
treatment to correct the anatomic problems before ECT. There are reports that elderly
patients with unrepaired small abdominal aortic aneurysms (range from 3.0 to 5.2 cm),
descending aortic aneurysm and aortic valve stenosis (≤1.0) under rigorous medical
management can be successfully treated with ECT [214–216].
Takotsubo cardiomyopathy is an acute and reversible ventricular dysfunction with abnormal
ECG findings, such as ST-T and QTc changes, in the absence of significant coronary artery
disease. It is typically mediated by catecholamines. During an ictal phase of ECT, when
sympathetic output significantly increases, catecholamines also markedly increase. There are
a number of case reports in the literature on Takotsubo cardiomyopathy associated with ECT
in postmenopausal women [217–222]. The abnormalities are usually reversible in a few
weeks. Some authors suggest administering β-blockers [218,219] because it has cardiac
protective effect if ECT is retried. Early recognition and treatment of Takotsubo
cardiomyopathy, with consultation from cardiology and anesthesiology, may allow ECT to
be continued. In summary, ECT can be given with relative safety to elderly patients with
cardiovascular disease.
Pulmonary complications
Pre-ECT treatment of chronic obstructive pulmonary disease to optimize lung capacity is
essential. Theophylline, although seldom used in current practice, has been associated with
higher risk of prolonged seizures during ECT, even within therapeutic blood levels [223].
For patients with history or family history of pseudocholinesterase deficiency, prolonged
apnea may occur during ECT, when succinylcholine is used as a muscle relaxant [224].
Nondepolarizing muscle relaxants can be used alternatively. In a retrospective chart review,
elderly patients who had active asthma underwent ECT for severe depression. It was
concluded that ECT was safe and well tolerated, although four patients experienced five
transient but reversible asthma exacerbations [225]. Based on individual needs, patients with
active asthma should use their inhalers shortly before ECT treatment.
Postictal delirium & confusion
Benzodiazepine withdrawal, coadministration of ECT with bupropion [226], lithium [227],
dopaminergic drugs (e.g., L-dopa) [228] and theophylline [223] may contribute to post-ECT
delirium and prolonged confusion. Elderly patients with underlying neuropsychiatric
conditions, such as cognitive impairment [229], Parkinson’s disease/parkinsonism
[228,230], dementia [231,232] and stroke [233,234] are at a higher risk of developing
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delirium and confusion immediately after ECT. A study compared the incidence of ECT-
induced delirium in 14 depressed elderly patients who had a history of stroke with 14
depressed elderly controls (without a history of cerebrovascular accident) and found no
difference in the overall incidence rates of delirium between the two groups (28.5%) [235].
Some patients who had a recent cerebrovascular accident involving the caudate nucleus
appeared more likely to develop delirium in one study [234].
Reducing a half of the regular dosage of antiparkinsonian drug before initiating ECT might
prevent post-ECT delirium related to dopamine toxicity [228]. Some authors suggested that
done-pezil was helpful in shortening the duration of delirium and agitation [236]. Others
suggested intravenous benzodiazepines, propofol and higher doses of succinylcholine might
decrease the severity of post-ECT delirium [229,237,238]. In general, delirium and
confusion are transient and reversible [183,235]. ECT may be withheld when a patient has
prolonged post-ECT confusion or becomes delirious. Further investigation (e.g.,
neuroimaging and electrolytes) may be needed in elderly patients with pre-existing medical
illness and cerebrovascular disease. Although adverse cerebrovascular events due to
increased intracranial pressure associated with increased cerebral blood flow during ECT are
rare, the appearance of delirium in elderly patients should be monitored very closely and
treated without delay. If the condition does not resolve within a reasonable time frame,
neurology or neurosurgery consultation should be considered.
Cognitive side effects
Prudic and colleagues conducted a prospective, naturalistic study on the effectiveness of
ECT involved 347 patients at seven hospitals in metropolitan New York City (NY, USA)
[185]. The study assessed patients at baseline, immediately post-ECT, and 6 months post-
ECT, and found no difference in the efficacy of ECT but marked differences in cognitive
impairment associated with different techniques. Sine wave had worse cognitive impairment
compared with brief pulse; BL electrode placement had greater deficits at post-ECT than
RUL electrode placement; retrograde amnesia for autobiographical information was greater
with BL electrode placement than RUL electrode placement in 6-month follow-up. On the
other hand, most patients who received RUL ECT, showed cognitive improvement
compared with baseline by 6 months. In addition, higher stimulus intensity over seizure
threshold is associated with more cognitive side effects. In a RCT, ultrabrief pulse ECT had
a better post-ECT autobiographical and anterograde memory side-effect profile than brief
pulse ECT [239].
The frequency of the ECT, but not the total number of ECT treatments in a lifetime, predicts
the degree of cognitive impairment post-ECT [240]. Older age, female gender and low
baseline cognitive performance increase the degree of risk for adverse cognitive impairment
with ECT [241]. Presence of depressive symptoms increases complaints of cognitive
difficulties in many settings. Some authors suggest that side effects of ECT are mainly
depressive phenomena and are independent of age [242]. Brodaty and colleagues assessed
81 patients (mean age 7 years) with major depression prospectively pre-ECT, immediately
post-ECT and 1–3 years later [243]. Tests on anterograde memory, reaction time, attention,
concentration, speed of cognitive processing and fluency were used; there were no tests on
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retrograde memory function. The study did not find impairment on these tests more
pronounced directly after ECT or at follow-up in older patients, suggesting the improvement
of depression in post-ECT correlated with reduction of side effect burden. Assessing elderly
depressed patients’ cognitive functioning is complex and multifactorial. At this time, the
effect of ECT in elderly patients’ cognition remains incompletely described.
C-ECT & M-ECT
C-ECT may be required in the first 6 months after a remission with acute ECT treatment.
The recommended post-ECT continuation pharmacotherapy is combined lithium and
antidepressant. If a patient fails standard pharmacotherapy following a successful course of
ECT, C-ECT should be considered in order to decrease the likelihood of relapse [244]. The
goal of C-ECT is to prevent relapse while M-ECT, beginning 6 months after C-ECT, is used
to prevent recurrence. Kellner and colleagues [245] evaluated the comparative efficacy of C-
ECT and the combination of lithium plus nortriptyline (continuation pharmacotherapy) after
a successful acute ECT course. There were 201 depressed patients in the study, including 66
elderly patients. This multisite randomized trial found that both C-ECT and continuation
pharmacotherapy reduced relapse rates, and had no age differences in the rates of response
and symptom remission [245].
Medication resistance during the index episode predicts a higher rate of relapse [59]. A
retrospective chart review of 58 elderly patients with recurrent MDD or bipolar depression
showed that rates of admission to hospital fell by 53% in number and 79% in duration in the
2 years after continuation–maintenance ECT began, and the rates of admission fell by 90%
in number and 97% in duration within the actual treatment period [246]. A recent literature
review concluded that M-ECT is as effective as maintenance medication after a successful
course of ECT and is well tolerated in elderly depressed patients [247]. There are no
established C-ECT and M-ECT treatment schedules. Usually, an ECT taper bridges the
acute treatment to the continuation treatment. Typically, weekly ECT is given during the
first month after acute treatment; then tapered to every other week ECT in the following 1 or
2 months; and tapered further to monthly ECT thereafter. The frequency of C-ECT or M-
ECT should be modified to meet an individual patient’s needs.
Besides affective disorders, M-ECT is utilized in treatment-resistant schizophrenia. A
controlled study reported the combined treatment with ECT and antipsychotic drugs was
superior to ECT alone or medication alone in relapse prevention [248]. M-ECT has been
shown to be effective in preventing relapse in catatonic schizophrenia patients [42]. For
patients who have severe Parkinson’s disease comorbid with affective disorder, M-ECT can
benefit both illnesses. In elderly patients, the most concerning side effects of ECT are
anterograde and retrograde amestic memory impairment. A placebo-controlled study of
cognitive function related to ECT suggested that the administration of a large number of
ECT (over 100 life time ECT treatments), spaced over several courses, did not result in
long-term cognitive impairment [240]. Overall, C-ECT and M-ECT are effective and should
be considered for elderly patients who can not tolerate medications and who are medication-
resistent, treatment refractory, or have severe medical comorbidities, limiting the use of
pharmacotherapy.
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Conclusion & future perspective
Currently, ECT is still the most widely available nonpharmacologic treatment procedure for
severe mental illness, although newer neuromodulation therapies are being developed. These
newer brain stimulation modalities include more invasive procedures, such as vagal nerve
stimulation, deep brain stimulation and epidural cortical stimulation, and less invasive
procedures, such as transcranial magnetic stimulation, transcranial direct current stimulation
and magnetic seizure therapy (MST). Only transcranial magnetic stimulation and vagal
nerve stimulation are US FDA approved. As discussed elsewhere in this review, the cardiac
and cognitive side-effect profiles of ECT are the major concerns of practicing ECT in the
geriatric population. MST is an experimental brain stimulation technique that involves a
magnetically induced seizure. MST presumably has a better localization of the site of
initiation and focalization of propagation [249], which could cause fewer cognitive side
effects and possibly have less impact on parasympathetic and sympathetic outflow, which
cause HR and BP fluctuation [250]. However, the efficacy of MST in the treatment of
depression has not been established [251], although MST has been found to be associated
with rapid reorientation and intact anterograde and retrograde memory [252]. Elderly
patients may benefit from MST because of its favorable side-effect profile compared with
ECT if antidepressant effect of MST is comparable with or superior to ECT, and the
treatment becomes FDA approved.
Adverse cognitive effects are a major factor limiting the use of ECT. Work continues on
reducing cognitive adverse effects, and placing electrodes near specific anatomic areas of
the brain, which are functionally related to mood and behavior while sparing areas
associated with learning, memory and cognition. FEAST trial [301] is an example. Various
strategies for improving cognitive and memory deficits following ECT, such as Cognitive
Training for Memory Deficits Associated with ECT [302], are based on the evidence that
cognitive remediation improves memory performance in epilepsy. As mentioned earlier in
this review, a marked suprathreshold dose improves efficacy of ECT, but yields more severe
acute or short-term cognitive side effects. Future clinical and research studies should also
focus on how and when to utilize ECT as a powerful synergistic therapy, to enhance other
biological therapies and psychotherapy, and prevent symptom relapse or recurrence.
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- Electroconvulsive therapy (ECT) may be the most effective and
rapid treatment available for elderly patients who have severe
major depressive disorder, or bipolar mania or bipolar
depression.
- Current ECT practice guidelines recommend ECT as an
augmentation strategy in treatment-refractory schizophrenia.
■ Neuropsychiatric disorders
- Elderly patients with catatonia, including schizophrenia with
intractable catatonia, delirious mania with catatonic features,
neuroleptic malignant syndrome and catatonia secondary to
critical medical conditions, can be treated effectively with acute
ECT.
- ECT can be an effective treatment for psychosis induced by
antiparkinsonian drugs.
- ECT can improve motor function in severe idiopathic
Parkinson’s disease with ‘on–off’ phenomena.
- ECT is a well-tolerated and effective treatment for poststroke
depression and for dementia with potentially life-threatening
behavioral disturbances, depression and psychosis.
■ Continuation ECT & maintenance ECT
- Continuation ECT and maintenance ECT are effective in elderly
patients.
■ ECT adverse effects & management
- Delirium and confusion are transient and reversible in most
cases.
- ECT can be given with relative safety to elderly patients with
severe cardiovascular disease, chronic obstructive pulmonary
disease and active asthma, when treatment for cardiac or
pulmonary conditions before ECT is optimized.
■ Maximizing ECT efficacy & minimizing ECT side effects
- Right unilateral ECT has fewer cognitive adverse effects than
bilateral ECT while efficacy can be made equivalent to bilateral
ECT with adequate dosing.
- Stimulus intensity for unilateral ECT should be 2.5- to 8-times of
seizure threshold to yield the best ECT effectiveness.
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- Right unilateral ECT appears to be optimal in elderly patients.
■ Pre-ECT evaluation
- A multidisciplinary evaluation team should include a treating
psychiatrist, an ECT psychiatrist, and an anesthesiologist.
- A written informed consent for ECT is the standard of care.
- Neuroimaging should be obtained in elderly patients with a
sudden onset of neuropsychiatric condition.
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Table 1
Differences between brief pulse and ultrabrief pulse stimuus.
Electrical waveform History utilization Seizure induction Memory problems Pulse
width (ms)
Brief pulse 1970s–present Efficient Moderate 0.5–2.0
Ultrabrief pulse 1990s–present More efficient Limited <0.5






















Kerner and Prudic Page 35
Table 2
Differences among anesthetic agents and muscle relaxants.
Drug Dose (mg/kg) Benefits Side effects
Anesthetic agents
Methohexital 0.75–1.0 Rapid action
Less post-ECT confusion
–
Thiopental 2.0–4.0 – Increased risk of bradycardia
Propofol 1.0–1.5 Less cardiotoxicity
Shorter half-life
Reduced duration of seizure
Etomidate 0.15–0.3 Minimal cardiac side effects;
low anticonvulsant effects
Post-ECT confusion
Ketamine 1.5–2.0 – Cardiotoxicity
Transient psychosis
Muscle relaxants
Succinylcholine 0.5–1.25 Rapid onset
Fast offset
Hyperkalemia
Mivacurium 0.2 Alternative to succinylcholine Longer acting; requires reversal
ECT: Electroconvulsive therapy.
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Table 3





Antidepressant efficacy Cognitive side
effects




Possibly less than bilateral
Bilateral Bifrontotemporal Higher Standard Significant
R-unilateral R-frontotemporal
R-centroparietal
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